AR032298A1 - Compuestos derivados de pirazolo[4,3-e]diazepinas, composicion farmaceutica que los contienen, su uso como productos medicinales y proceso para prepararlos - Google Patents
Compuestos derivados de pirazolo[4,3-e]diazepinas, composicion farmaceutica que los contienen, su uso como productos medicinales y proceso para prepararlosInfo
- Publication number
- AR032298A1 AR032298A1 ARP010100024A ARP010100024A AR032298A1 AR 032298 A1 AR032298 A1 AR 032298A1 AR P010100024 A ARP010100024 A AR P010100024A AR P010100024 A ARP010100024 A AR P010100024A AR 032298 A1 AR032298 A1 AR 032298A1
- Authority
- AR
- Argentina
- Prior art keywords
- nitrogen
- oxygen
- sulfur
- optionally interrupted
- linear
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
Abstract
Un compuesto derivado de pirazolo[4,3-e]diazepinas, de la formula (1), donde: R1 se elige de los siguientes grupos: hidrogeno; alquilo C1-6 lineal o ramificado; cicloalquilo C3-6; alquilcicloalquilo que comprende un grupo alquilo C1-6 y un grupo cicloalquilo C3-6; arilo C5-10, optativamente interrumpido con un heteroátomo elegido de nitrogeno, oxígeno y azufre; arilalquilo C6-10, optativamente interrumpido con un heteroátomo elegido de nitrogeno, oxígeno y azufre; alquilarilo C6-10, optativamente interrumpido con un heteroátomo elegido de nitrogeno, oxígeno y azufre; alquenilo C2-6 lineal o ramificado; los grupos (CH2)nORB, (CH2)nCF3, (CH2)nC(O)RB, (CH2)nCOORB, (CH2)nOC(O)RA, (CH2)nSRB, (CH2)nC(S)RB, (CH2)nC(S)ORB, (CH2)nC(S)SRB, (CH2)nNRBRC, (CH2)nC(O)NRBRC, (CH2)nNRCC(O)RB, (CH2)nNRDC(O)NRDRB o (CH2)nZ, donde: RA se elige de alquilo C1-6 lineal o ramificado; cicloalquilo C3-6; alquilcicloalquilo que comprende un grupo alquilo C1-6 y un grupo cicloalquilo C3-6; arilo C5-10, optativamente interrumpido con un heteroátomo elegido de nitrogeno, oxígeno y azufre; arilalquilo C6-10, optativamente interrumpido con un heteroátomo elegido de nitrogeno, oxígeno y azufre; alquilarilo C6-10, optativamente interrumpido con un heteroátomo elegido de nitrogeno, oxígeno y azufre; alquenilo C2-6 lineal o ramificado; RB y RC, que pueden ser idénticos o diferentes, se eligen de: hidrogeno, alquilo C1-6 lineal o ramificado; cicloalquilo C3-6; alquilcicloalquilo que comprende un grupo alquilo C1-6 y un grupo cicloalquilo C3-6; arilo C5-10, optativamente interrumpido con un heteroátomo elegido de nitrogeno, oxígeno y azufre; arilalquilo C6-10, optativamente interrumpido con un heteroátomo elegido de nitrogeno, oxígeno y azufre; alquilarilo C6-10, optativamente interrumpido con un heteroátomo elegido de nitrogeno, oxígeno y azufre: alquenilo C2-6 lineal o ramificado; siendo posible que RB y RC formen un anillo que contiene de 5 a 7 átomos de C que pueden incluir uno o más heteroátomos elegidos de S, N y O; RD es hidrogeno o alquilo C1-6 lineal o ramificado; Z es un halogeno; y n es un numero entero de 0 a 4 inclusive; R2 se elige de los siguientes grupos: alquilo C1-6 lineal o ramificado; alquilcicloalquilo que comprende un grupo alquilo C1-6 y un grupo cicloalquilo C3-6; cicloalquilo C3-6; arilo C5-10, optativamente interrumpido con un heteroátomo elegido de nitrogeno, oxígeno y azufre; alquilarilo C6-10, optativamente interrumpido con un heteroátomo elegido de nitrogeno, oxígeno y azufre; alquenilo C2-6 lineal o ramificado; los grupos (CH2)mORB, (CH2)mCF3, (CH2)mC(O)RB, (CH2)mCOORB, (CH2)mOC(O)RA, (CH2)mSRB, (CH2)mC(S)RB, (CH2)mC(S)ORB, (CH2)mC(S)SRB, (CH2)mNRBRC, (CH2)mC(O)NRBRC, (CH2)mNRCC(O)RB, (CH2)mNRDC(O)NRDRB o (CH2)mZ, en donde: RA, RB, RC, RD y Z son lo definido anteriormente, y m es un numero entero de 1 a 4 inclusive; R3 se elige de los siguientes grupos: hidrogeno; alquilo C1-6 lineal o ramificado; cicloalquilo C3-6; alquilcicloalquilo que comprende un grupo alquilo C1-6 y un grupo cicloalquilo C3-6; arilo C5-10, optativamente interrumpido con un heteroátomo elegido de nitrogeno, oxígeno y azufre; arilalquilo C6-10, optativamente interrumpido con un heteroátomo elegido de nitrogeno, oxígeno y azufre; alquilarilo C6-10, optativamente interrumpido con un heteroátomo elegido de nitrogeno, oxígeno y azufre; alquenilo C2-6 lineal o ramificado; los grupos (CH2)nORB, (CH2)nCF3, (CH2)nC(O)RB, (CH2)nCOORB, (CH2)nOC(O)RA, (CH2)nSRB, (CH2)nC(S)RB, (CH2)nC(S)ORB, (CH2)nC(S)SRB, (CH2)nNRBRC, (CH2)nC(O)NRBRC, (CH2)nNRCC(O)RB, (CH2)nNRDC(O)NRDRB o (CH2)nZ, en donde: RA, RB, RC, RD, y n son lo definido anteriormente; los grupos arilo, arilalquilo, y alquilarilo definidos anteriormente son no sustituidos o sustituidos en el grupo arilo con 1, 2, o 3 grupos elegidos de: halogeno, hidroxilo, NO, NO2, CN, alcoxi C1-4, (CH2)nORB, (CH2)nNRBRC, (CH2)nNC(O)RB, (CH2)nHNSO2RB, (CH2)nN(SO2RB)2, CO2RB, CF3 y un resto de formula (2), en donde RB, RC y n son lo definido anteriormente; y la línea de puntos presente en la formula (1) indica que la union entre W y el carbono en la posicion 5 puede ser: una sola union, en cuyo caso W representa un átomo de nitrogeno sustituido con un átomo de hidrogeno; o una union doble, y en este caso W representa un átomo de carbono no sustituido; X es S, O, N-CN o N-RB en donde RB es lo definido anteriormente; así como los oxidos, las formas tautomeras y los isomeros opticos correspondientes o los derivados farmacéuticamente aceptables de los compuestos de la formula (1), con la salvedad de que cuando R1 representa un grupo metilo, R2 un grupo etilo, W es N, X es un átomo de oxígeno y la union entre W y el átomo de carbono en la posicion 5 es una doble union, entonces R3 no es ni un grupo fenilo no sustituido ni un grupo fenilo que lleva un átomo de fluor en una posicion orto como unico sustituyente. Composicion farmacéutica que comprende al menos un compuesto de la formula (1) y un vehículo farmacéuticamente aceptable. Se usan para tratar cáncer, síndrome de inmunodeficiencia adquirida, fibrosis, cicatrices, osteoartritis y otras terapias con inhibidor de la fosfodiesterasa 4, definidas en la memoria. Proceso para preparar dicho compuesto que comprende ciclizacion, tionizacion, reaccion con H2N-CN, reduccion y reaccion con H2N-RB.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0000095A FR2803299B1 (fr) | 2000-01-05 | 2000-01-05 | NOUVELLES PYRAZOLO [4,3-e] DIAZEPINES SUBSTITUEES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, UTILISATION A TITRE DE MEDICAMENT ET PROCEDES POUR LEUR PREPARATION |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR032298A1 true AR032298A1 (es) | 2003-11-05 |
Family
ID=8845641
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010100024A AR032298A1 (es) | 2000-01-05 | 2001-01-03 | Compuestos derivados de pirazolo[4,3-e]diazepinas, composicion farmaceutica que los contienen, su uso como productos medicinales y proceso para prepararlos |
Country Status (42)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1199074A1 (en) * | 2000-09-15 | 2002-04-24 | Warner-Lambert Company | Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production |
| EP1188438A1 (en) * | 2000-09-15 | 2002-03-20 | Warner-Lambert Company | Pharmaceutical composition for preventing or treating a disease associated with an excess of Il-12 production |
| TW200745106A (en) * | 2005-10-03 | 2007-12-16 | Astrazeneca Ab | Chemical compounds |
| KR20160080799A (ko) | 2014-12-30 | 2016-07-08 | 한국해양과학기술원 | 금 촉매를 이용한 α-피론 유도체 전합성 방법 및 이에 의해 합성되어 인간 암세포주에 세포독성을 가지는 α-피론 유도체 |
| EP3551632B1 (en) | 2016-12-12 | 2024-06-12 | UNION therapeutics A/S | Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors |
| US10906915B2 (en) | 2016-12-12 | 2021-02-02 | Leo Pharma A/S | Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors |
| DK3551634T3 (da) | 2016-12-12 | 2021-06-14 | Union Therapeutics As | Substituerede pyrazoloazepin-8-oner og anvendelse deraf som phosphodiesterasehæmmere |
| TWI812739B (zh) * | 2018-06-21 | 2023-08-21 | 景凱生物科技股份有限公司 | Nadph氧化酶抑制劑、含其的醫藥組合物、及其應用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3764688A (en) * | 1972-07-27 | 1973-10-09 | Abbott Lab | 4,6-DIHYDRO-1,3-DIMETHYL-8-PHENYL-4-PROPARGYL-PYRAZOLO {8 4,3-e{9 {0 DIAZEPIN-5 (1H) ONE IN TREATING INFLAMMATION |
-
2000
- 2000-01-05 FR FR0000095A patent/FR2803299B1/fr not_active Expired - Fee Related
- 2000-12-23 DZ DZ000158A patent/DZ3103A1/xx active
- 2000-12-27 JP JP2001550229A patent/JP2003519233A/ja active Pending
- 2000-12-27 PL PL00356668A patent/PL356668A1/xx not_active Application Discontinuation
- 2000-12-27 TR TR2002/01719T patent/TR200201719T2/xx unknown
- 2000-12-27 EP EP00991657A patent/EP1248787B1/en not_active Expired - Lifetime
- 2000-12-27 AT AT00991657T patent/ATE278692T1/de not_active IP Right Cessation
- 2000-12-27 NZ NZ519520A patent/NZ519520A/en unknown
- 2000-12-27 OA OA1200200203A patent/OA12134A/en unknown
- 2000-12-27 SK SK940-2002A patent/SK9402002A3/sk unknown
- 2000-12-27 HU HU0204213A patent/HUP0204213A2/hu unknown
- 2000-12-27 EE EEP200200373A patent/EE200200373A/xx unknown
- 2000-12-27 CA CA002396315A patent/CA2396315A1/en not_active Abandoned
- 2000-12-27 CZ CZ20022222A patent/CZ20022222A3/cs unknown
- 2000-12-27 ES ES00991657T patent/ES2226978T3/es not_active Expired - Lifetime
- 2000-12-27 WO PCT/EP2000/013380 patent/WO2001049689A2/en active Search and Examination
- 2000-12-27 CN CN00818202A patent/CN1420888A/zh active Pending
- 2000-12-27 IL IL15039400A patent/IL150394A0/xx unknown
- 2000-12-27 EA EA200200610A patent/EA005071B1/ru not_active IP Right Cessation
- 2000-12-27 AP APAP/P/2002/002572A patent/AP2002002572A0/en unknown
- 2000-12-27 BR BR0016926-9A patent/BR0016926A/pt not_active Application Discontinuation
- 2000-12-27 AU AU33678/01A patent/AU3367801A/en not_active Abandoned
- 2000-12-27 KR KR1020027008692A patent/KR20020063293A/ko not_active Application Discontinuation
- 2000-12-27 MX MXPA02006618A patent/MXPA02006618A/es active IP Right Grant
- 2000-12-27 DE DE60014712T patent/DE60014712T2/de not_active Expired - Fee Related
-
2001
- 2001-01-03 AR ARP010100024A patent/AR032298A1/es not_active Application Discontinuation
- 2001-01-03 PE PE2001000003A patent/PE20011041A1/es not_active Application Discontinuation
- 2001-01-03 TN TNTNSN01001A patent/TNSN01001A1/fr unknown
- 2001-01-03 UY UY26517A patent/UY26517A1/es not_active Application Discontinuation
- 2001-01-03 PA PA20018509601A patent/PA8509601A1/es unknown
- 2001-01-04 SV SV2001000253A patent/SV2001000253A/es not_active Application Discontinuation
- 2001-01-04 HN HN2001000002A patent/HN2001000002A/es unknown
- 2001-01-04 CO CO01000514A patent/CO5290255A1/es not_active Application Discontinuation
- 2001-01-04 GT GT200100002A patent/GT200100002A/es unknown
-
2002
- 2002-06-19 IS IS6437A patent/IS6437A/is unknown
- 2002-07-01 CR CR6693A patent/CR6693A/es not_active Application Discontinuation
- 2002-07-02 BG BG106893A patent/BG106893A/xx unknown
- 2002-07-02 ZA ZA200205287A patent/ZA200205287B/en unknown
- 2002-07-03 MA MA26719A patent/MA26863A1/fr unknown
- 2002-07-04 NO NO20023249A patent/NO20023249L/no not_active Application Discontinuation
- 2002-07-05 HR HR20020577A patent/HRP20020577A2/hr not_active Application Discontinuation
-
2003
- 2003-03-24 HK HK03102129.7A patent/HK1050002A1/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2525763T3 (es) | Derivados del ácido fenilalcanoico sustituido y sus usos para el tratamiento de enfermedades respiratorias | |
| CO5590895A2 (es) | Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos | |
| HUP0302771A2 (hu) | Nitrozo-difenilamin-származékok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| HUP0202501A2 (hu) | Pirimidin-2,4,6-trion metalloproteináz inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| ES2082755T3 (es) | Derivados de acido 3-desmetil-mevalonico, procedimiento para su preparacion, preparados farmaceuticos a base de estos compuestos, su utilizacion asi como productos intermedios. | |
| SE444809B (sv) | Alfa-skyddade oxiimino-beta-oxo-gamma-halogensmorsyraderivat till anvendning som mellanprodukt for framstellning av farmaceutiskt anvendbara cefemforeningar | |
| CO5690577A2 (es) | Derivados de imidazoquinolina como ligandos receptores de adenosina a3 | |
| UY28528A1 (es) | Nuevos compuestos | |
| DK1339412T3 (da) | Formulering, som indeholder phosphatderivater af elektronoverførselsmidler | |
| ES2123652T3 (es) | 7-(2-aminoetil)-benzotiazolonas. | |
| AR032298A1 (es) | Compuestos derivados de pirazolo[4,3-e]diazepinas, composicion farmaceutica que los contienen, su uso como productos medicinales y proceso para prepararlos | |
| ES2042807T3 (es) | 6-fenil-dihidro-3(2h)-piridazinonas, procedimiento para su preparacion, y medicamentos que contienen estos compuestos. | |
| AR036176A1 (es) | Un derivado de fenil-acetamido-tiazol, un procedimiento para su preparacion, una composicion farmaceutica que lo comprende, un producto o kit que los comprende, y un metodo que utiliza dicho derivado | |
| AR036074A1 (es) | Derivados de aminoquinolina, las composiciones farmaceuticas que los contienen, el uso de los mismos para la preparacion de una composicion farmaceutica, un procedimiento para su preparacion y los intermediarios empleados en dicho procedimiento de preparacion | |
| SE9003973L (sv) | Glycerol, ett framstaellningsfoerfarande foer desamma samt terapeutiska kompositioner innehaallande dem | |
| SE7501002L (es) | ||
| DK0452204T3 (da) | Hidtil ukendte 3-aminochromanderivater, fremgangsmåde til fremstilling heraf og farmaceutiske midler, som indeholder dem | |
| AR035599A1 (es) | Compuestos 1,8-naftiridina, dihidroquinolina y piridol[1,2,3-de][1,4]benzoxazina sustituidos, medicamentos, agentes terapeuticos, metodos de produccion y usos en la produccion de un medicamento, de un agente antibacteriano y de un agente para tratar una enfermedad infecciosa | |
| PT861250E (pt) | Derivados de amidina e de isotioureia como inibidores de oxido nitrico sintase | |
| AR012553A1 (es) | Una composicion que posee propiedades antivirales, en base a 7h-benz (de) antracenos y las composiciones farmaceuticas que los contienen conjuntamentecon derivados de la benzantrona | |
| AR034557A1 (es) | Derivados de (2-azabiclo[2.2.1]hept-7-il)metanol como agonistas de receptores nicotinicos de acetilcolina | |
| DK351982A (da) | Fremgangsmaade til fremstilling af aminoglycosidderivater | |
| SE9904676D0 (sv) | Novel compounds | |
| SE7614537L (sv) | Forfarande for framstellning av n?721-(2-tetra - hydrofuryl)-5-fluoruracil | |
| SE7705473L (sv) | Forfarande for framstellning av naftylderivat |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |